A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years

Xin Cheng, Gan Zhao, Aihua Dong, Zhonghuai He, Jiarong Wang, Brian Jiang, Bo Wang, Miaomiao Wang, Xuefen Huai, Shijie Zhang, Shuangshuang Feng, Hong Qin, Bin WangmedRxiv 2022 · DOI

TL;DR

This paper details the first-in-human trial of BARS13, a recombinant RSV vaccine that targets the viral G protein rather than the more common F protein. The study demonstrates that the vaccine is safe, well-tolerated, and successfully induces a robust antibody response in healthy adults, particularly when administered in a two-dose regimen.

What Problem Does This Paper Address?

Respiratory Syncytial Virus (RSV) is a global health burden, causing millions of cases of pneumonia and bronchiolitis annually, primarily in infants and the elderly. Despite its impact, the road to an effective vaccine has been rocky. In the 1960s, a formalin-inactivated RSV vaccine (FI-RSV) famously failed, leading to vaccine-enhanced disease (VED)—where vaccinated children actually suffered worse symptoms upon natural infection.

Most modern RSV vaccines target the "F" (fusion) protein. However, the authors of this study focus on the "G" (attachment) protein. The G protein contains stable neutralizing epitopes that are less dependent on complex protein folding than the F protein. The challenge lies in creating a G-protein vaccine that triggers a protective immune response without the risk of VED.

Methods

The researchers conducted a Phase I, randomized, double-blind, placebo-controlled dose-escalation study in Melbourne, Australia.

  • Participants: 60 healthy adults (aged 18–45).
  • The Vaccine (BARS13): A unique formulation consisting of a purified recombinant RSV-G protein (the antigen) and Cyclosporine A (CsA).
  • The Twist: While CsA is typically known as an immunosuppressant used in organ transplants, here it acts as a novel immunomodulator. Preclinical data suggested that at specific ratios, CsA helps induce T regulatory cells (Tregs), which can suppress the over-reactive Th2-type inflammation associated with VED.
  • Regimens: Participants were split into low-dose and high-dose groups, receiving either a single injection (Day 0) or a repeat dose (Days 0 and 30).

Datasets

As a clinical trial, the "dataset" consists of the 60-person study cohort.

  • Demographics: The majority (76.7%) were white females, with a mean age of approximately 27 years.
  • Evaluation: Safety was monitored via diary cards and clinical exams. Immunogenicity was measured using ELISA (for IgG and neutralizing antibodies) and flow cytometry (for T-cell proliferation and cytokine production).

Key Insights and Ideas

  • The G-Protein Advantage: By targeting the G protein's central conserved domain (CCD), the vaccine aims for "strain-independent" neutralization, potentially offering broader protection across different RSV variants.
  • CsA as a Safety Valve: The most innovative aspect is using CsA to "steer" the immune system. By promoting a tolerogenic environment via Tregs, the researchers hope to circumvent the historical pathology of RSV vaccines.
  • Dosing Matters: The study confirmed that a prime-boost (repeat dose) strategy is significantly more effective than a single shot, showing a clear upward trend in antibody titers by Day 60.

Key Results

  • Safety: No Serious Adverse Events (SAEs) were reported. The most common side effects were local pain/tenderness and fatigue, which were mostly mild and resolved quickly.
  • Antibody Response: All participants were seropositive at baseline (due to prior natural exposure), but BARS13 successfully boosted these levels.
  • The Geometric Mean Fold Increase (GMFI) for IgG was over 3-fold in the repeat-dose groups by Day 60.
  • Neutralizing antibody concentrations in the high-dose repeat group reached a median of 2499.6 IU/mL at Day 60, a significant jump from baseline.
  • Cellular Response: T-cell analysis showed that the vaccine did not induce an over-reactive inflammatory response, supporting the hypothesis that the CsA-modulated formulation is safe from a VED perspective.

Limitations and Future Work

The authors acknowledge several hurdles for the next phases:

  1. Small Sample Size: As a Phase I trial, the cohort is too small to make definitive claims about efficacy or rare side effects.
  2. Follow-up Duration: The 60-to-90-day follow-up is relatively short; longer-term data is needed to see how long the protection lasts.
  3. Standardization: The authors note a need for benchmarking their results against international standards to make them more comparable to other RSV vaccine candidates (like those from Pfizer or GSK).
  4. PBMC Retrieval: Some T-cell data was lost or rendered "tentative" due to the challenges of long-term cryopreservation of blood samples.

Overall, BARS13 represents a promising alternative to F-protein-focused vaccines, proving that the G protein—when paired with the right immunomodulator—is a viable target for the next generation of RSV prophylaxis.

Summary updated

Abstract

Abstract Background With enormous morbidity and mortality induced by respiratory syncytial virus (RSV) infection among infants and the elderly, vaccines against RSV infection are in huge market demand. Methods We conducted a First-in-human (FIH), randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety and immunogenicity response of the rRSV vaccine (BARS13) in healthy adults aged 18-45. A total of 60 eligible participants were randomized in a 4:1 ratio to receive one of four dose levels or vaccination regimens of BARS13 or placebo. Results No serious adverse event (SAE) was experienced by any study participant. The geometric mean fold increase (GMFI) from baseline in all participants post-administration indicated that compared with single dose regimens, the IgG antibody level from baseline in participants received repeat dose regimens at Day 60 has increased over a 3-fold. Conclusions BARS13 has a generally good safety and tolerability profile, and no significant difference in terms of adverse reaction severity or frequency has been observed between different dose groups. The immune response in repeat dose recipients shows more potential in further study and has guiding significance for the dose selection of subsequent studies.
BibTeX
@misc{cheng2022first,
  author = {Xin Cheng and Gan Zhao and Aihua Dong and Zhonghuai He and Jiarong Wang and Brian Jiang and Bo Wang and Miaomiao Wang and Xuefen Huai and Shijie Zhang and Shuangshuang Feng and Hong Qin and Bin Wang and Bin Wang and Bin Wang},
  title = {{A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years}},
  year = {2022},
  doi = {10.1101/2022.12.27.22283128},
  howpublished = {medRxiv},
}
Figure